臨床醫學參考文獻

　　臨床醫學主要研究疾病的病因、診斷、治療和預后，致力于提高臨床治療水平，促進人體健康。

　　臨床醫學參考文獻范文一：

　　高等醫學院校《中醫學》課程分段教學改革思路 羅永兵 中醫教育 2006年12月

　　回歸醫學科學的`人文精神 趙春妮 國醫論壇 2004年6月

　　淺談如何搞好對西醫學生的中醫教育 趙春妮 瀘州醫學院學報 2004年6月

　　從《內經》“七損八益”看中醫學與中國傳統文化 趙春妮 內蒙古中醫藥 2005年4月

　　如何把握方劑教學中的兩個重點 王全 中醫教育 2006年10月

　　我院中西醫結合方向人才培養模式下內經教學改革探索與實踐 魏嵋 時珍國醫國藥 2007年1月

　　從八綱辯證談中醫CAI課件制作與開發 江花 中國現代醫學技術雜志 2008年1月

　　臨床醫學參考文獻范文二：

　　中醫學 李家邦 人民衛生出版社 2005年1月第6版

　　中醫學 王桂敏 科學出版社 2007年3月第1版

　　中醫基礎理論 郭霞珍 上海科學技術出版社 2006年8月第一版

　　中醫內科學 王永炎 北京出版社 1994年12月第一版

　　方劑學 鄧中甲 中國中醫藥出版社 2003年1月第一版

　　中華臨床中醫學 雷載權 &nbswww.med126.com/zhicheng/p;人民衛生社 1998年10月第一版

　　臨床醫學參考文獻范文三：

　　[1]Baughman KL.Diagnosis of myocarditis: death of Dallas criteria.Circulation2006;113:593-595.

　　[2]Lieberman EB,Hutchins GM,Herskowitz A'et al.Clinicopathologic descriptionof myocarditis J. J Am Coll Cardiol, 1991; 18(7)： 1671-1626.

　　[3]汪翼。小兒暴發性心肌炎的診斷與病原治療[J].小兒急救醫學，2003;10(3);129-130.

　　[4]Richardson P,McKenna W,Bristow M,et al. Report of the 1995 World HealthOrganization/International Society and Federation of Cardiology Task Force onthe Definition and Classification of Cardiomyopathies.Circulation,1996;93:841-842.

　　[5]中華醫學會兒科學會心血管組。病毒性心肌炎診斷標準[J].中華兒科雜志，2000;38(2)：75-76.

　　[6] Nishii M,Inomata T,Takehana H,et al.Serum levels of interleukin-10 onadmission as a prognostic predictor of human fulminant myocarditis. J Am ollCardiol,2004;44:1292-1297.

　　[7] Smith SC,Ladenson JH,Mason JW,et al.Elevations of cardiac troponin Iassociated with myocarditis. Experimental and clinical correlates.Circulation, 1997;95:163-168.

　　[8]Soongswang J,Durongpisitkul K,Nana A,et al.Cardiac troponin T: a marker inthe diagnosis of acute myocarditis in children. Pediatr Cardiol,2005;26:45-49.

　　[9] Dao Q,Krishnaswamy P,Kazanergrar,et al.B-type natriureti. C petide indiagnosis of congestive heart failure in an urgent care setting[J].J AM CollCardiol,2001;37:379-385.

　　[10] Bay M?Kirk V,Pmer J,et al.NT-pro BNP:a new diagnostic screening tool todiffenmfiate bt31woo patients with lloftntd and reduced left ventrieularsystoliction[J].Heart?2003;89(2)： 150-154.

　　[11] Robert D,Harry J,Crijns,et al.Acute viral myocarditis. European HeartJournal,2008;29:2073-2082.

　　[12]Kuhlu,Pauschingerm,Seebergb,et al.Viral persistence in the myocardium isassociated with progressive cardiac dysfunction[J] .Circulation,2005 ; 112( 13)：1965-1970.

　　[13] Nakashima H,Katayama TJshizaki M,et al.Q wave and non-Q wavemyocarditis with special reference to clinical significance. Jpn Heart J,1998;39:763-774.

　　[14]Magnani JW, Danik HJ,Dec JR, et al. Survival in biopsy-proven myocarditis:a long-term retrospective analysis of the histopathologic,clinical,andhemodynamic predictors[J]. Am Heart J,2006; 151 (2)：463-470.

　　[15] Ukena C5Mahfoud F,Kindermann I,et al.Prognostic electrocardiographicparameters in patients with suspected myocarditis.Eur J Heart Fail,2011;13:398-405.

　　[16] Felker GM,Boehmer JP,Hruban RH,et al.Echocardiographic findings infulminant and acute myocarditis.J Am Coll Cardiol,2000;36:227_232.

　　[17]Abdel-Aty H,Simonetti O,Friedrich MG. T2-weighted cardiovascularmagnetic resonance imaging [J].J Magn Reson Imaging, 2007;26(3)：452-459.

　　[18]Abdel-Aty H,Boye P, Zagrosek A,et al. Diagnostic performance ofcardiovascular magnetic resonance in patients with suspected acute myocarditis:comparison of different approaches. J Am Coll Cardiol, 2005;45:1815-22.

　　[19]Skouri HN,Dec GW,Friedrich MG, et al. Nonivasive imaging in myocarditis.J Am Coll Cardiol, 2006;48(10)：2085-2093.

　　[20]Friedrich MG,Sechtem U,Schulz MJ,et al.Cardiovascular magnetic resonancein myocarditis: a JACC White Paper. J Am Coll Cardiol,2009;53:1475-1487.

　　[21] Mewton N,Liu CY,Croisille P,et al. Assessment of myocardial fibrosis withcardiovascular magnetic resonance. J Am Coll Cardiol, 2011;57(8)：891-903.

　　[22]Zhao SH.Recommendations for CMR in adults with CHD from the respectiveworking groups of the ESC:explanation and viewpoint.Chin J Magn ResonImaging,2010;1,4.

　　[23]Aretz HT. Myocarditis: the Dallas criteria. Hum Pathol, 1987; 18:619-624.

　　[24]Baughman KL.Diagnosis of myocarditisideath of Dallas criteria. Circulation,2006;113:593-595.

　　[25] Yilmaz A,Kindermann I,Kindermann M,et al. Comparative evaluation ofleft and right ventricular endomyocardial biopsy: differences in complication rateand diagnostic performance. Circulation?2010; 122:900-909.

　　[26] Kindermann I, Kindermann M,Kandolf R,et al. Predictors of outcome inpatients with suspected myocarditis. Circulation,2008;l 18:639-648.

　　[27]Dickstein K,Cohen SA,Filippatos G,et al. ESC Guidelines for the diagnosisand treatment of acute and chronic heart failure 2008: the Task Force for theDiagnosis and Treatment of Acute and Chronic Heart Failure 2008 of theEuropean Society of Cardiology. Eur Heart J?2008;29:2388-2442.

　　[28] Matsumori A,Igata H,Ono K,et al.High doses of digitalis increase themyocardial production of proinflammatory cytokines and worsen myocardialinjury in viral myocarditis: a possible mechanism of digitalis toxicity.Jpn CircJ,1999;63:934-940.

　　[29] Reinhartz 0,Hill JD,AlKhaldi A,et al.Thoratec ventricular assist devices inpediatric patients: update on clinical results.Asaio J,2005;51:501-503.

　　[30]Topkara VK,Dang NC,Barili F,et al.Ventricular assist device use for thetreatment of acute viral myocarditis.J Thorac Cardiovasc Surg,2006;131:1190-1191.

　　[31] Mirabel M,Luyt CE, Leprince P, et al Outcomes,long-term quality of life,and psychologic assessment of fulminant myocarditis patients rescued bymechanical circulatory support. Crit Care Med,2011 ;39:1029-1035.

　　[32]Rajagopal SK, Almond CS, Laussen PC,et al. Extracorporeal membraneoxygenation for the support of infants,children, and young adults with acutemyocarditis: a review of the Extracorporeal Life Support OrganizationRegistry.Crit Care Med,2010;38:382-387.

　　[33 ]European Heart Rhythm Association, Heart Rhythm Society, ZIPES D P,et al.ACC/AHA/ESC 2006 guidelines for management of patients with ventriculararrhythmias and the prevention of sudden cardiac death: a report of the AmericanCollege of Cardiology /American Heart Association Task Force and the EuropeanSociety of Cardiology Committee for Practice Guidelines (Writing Committee toDevelop Guidelines for Management of Patients With Ventricular Arrhythmiasand the Prevention of Sudden Cardiac Death)[J].J Am Coll Cardiol,2006;48(5)：247-346.

　　[34 ]McNamara DM,Holubkov R?Starling RC,et al. Controlled trial of intravenousimmune globulin in recent-onset dilated cardiomyopathy .Circulation,2001; 103:2254-2259.

　　[35] Amabile N,Fraisse A,Bouvenot J,et al. Outcome of acute fulminantmyocarditis in children. Heart (British Cardiac Society)， 2006;92:1269-1273.

　　[36] Drucker NA,Colan SD,Lewis AB,et al.Gamma-globulin treatment of acutemyocarditis in the pediatric population. Circulation, 1994;89:252-257.

　　[37]董瑞慶，楊俊華。心肌炎的診斷與治療現狀。新醫學，2011;42(2)：71-74.

　　[38] Felix SB,Staudt A?Landsberger M,et al.Removal of cardiodepressantantibodies in dilated cardiomyopathy by immunoadsorption.J Am Coll Cardiol,2002;39:646-652.

　　[39] Doesch AO, Konstandin M, Celik S, et al. Effects of protein Aimmunoadsorption in patients with advanced chronic dilated cardiomyopathy.!Clin Apher, 2009;24:141-149.

　　[40 ]Wang YX, Da CH, Vincelette J, et al. Antiviral and myocyte protective effectsof murine interferon-beta and -{alpha}2 in coxsackievirus B3-induced myocarditisand epicarditis in Balb/c mice. Am J Physiol,2007;293:69-76.

　　[41] Horwitz MS, La CA, Fine C, et al. Pancreatic expression of interferon-gammaprotects mice from lethal coxsackievirus B3 infection and subsequent myocarditis.Nat Med,2000;6:693-697.

　　[42] Okada I, Matsumori A,Matoba Y,et al. Combination treatment with ribavirinand interferon for coxsackievirus B3 replication. J Lab Clin Med,1992; 120:569-573.

　　[43] Matsumori A,Crumpacker CS,Abelmann WH. Prevention of viralmyocarditis with recombinant human leukocyte interferon alpha A/D in a murinemodel. J Am Coll Cardiol,1987;9:1320-1325.

　　[44] Kuhl U,Pauschinger M,Schwimmbeck PL,et al. Interferon-beta treatmenteliminates cardiotropic viruses and improves left ventricular function in patientswith myocardial persistence of viral genomes and left ventricular dysfunction.Circulation,2003;107:2793-2798.

　　[45]Blauwet LA, Cooper LT. Myocarditis. Prog Cardiovasc Dis,2010;52:274-288.

　　[46]McCarthy RE III,Boehmer JP,Hruban RH,et al. Long-term outcome offulminant myocarditis as compared with acute (nonfulminant) myocarditis. N EnglJMed,2000;342:690-695.

　　[47]Singh TP, Rabah R,Cooper LT,et al. Total lymphoid irradiation:newtherapeutic option for refractory giant cell myocarditis. J Heart Lung Transplant,2004;23:492-495.

　　[48]Magnani JW, Dec GW. Myocarditis: current trends in diagnosis and treatment.Circulation,2006;l 13:876-890.

　　[49]Sheppard R, Bedi M, Kubota T,et al. Myocard ial express ion of fas andrecovery of left ventxicu lar function in pat ien tsw ith recen t- on setcardiomyopathy [J], J Am Coll Cardiol,2005;46(6)： 1043-1044.

　　[50] Mendes LA, Dec GW, Picard MH,et al: Right ventricular dysfunction: anindependent predictor of adverse outcome in patients with myocarditis. Am HeartJ,1994;128:301-307.

　　[51]McCarthy RE, Boehmer JP, Hruban RH, et al. Long-term outcome offulminant myocarditis as compared with acute (nonfulminant) myocarditis. N EnglJ Med,2000;342:690-695.

　　[52] Mason JW, O'Connell JB,Herskowitz A,et al. A clinical trial ofimmunosuppressive therapy for myocarditis. The Myocarditis Treatment TrialInvestigators. N Engl J Med,1995;333:269-275.

　　[53] D'Ambrosio A,Patti G, Manzoli A,et al. The fate of acute myocarditisbetween spontaneous improvement and evolution to dilated cardiomyopathy: areview. Heart52001 ;85:499-504.

　　[54] Blauwet LA,Cooper LT.Myocarditis. Progress in Cardiovascular Diseases,2010;52:274-288.

【臨床醫學參考文獻】相關文章：

臨床醫學論文參考文獻02-14

臨床醫學畢業論文參考文獻06-02

精選臨床醫學畢業論文參考文獻02-14

臨床醫學畢業論文參考文獻精選01-27

臨床醫學專業論文參考文獻12-31

臨床醫學專業畢業論文參考文獻02-23

參考文獻01-24

MBA參考文獻01-09

參考文獻的寫法01-08